GURUFOCUS.COM » STOCK LIST » USA » NAS » Taysha Gene Therapies Inc (NAS:TSHA) » Definitions » Profitability Rank
Switch to:

Taysha Gene Therapies (NAS:TSHA) Profitability Rank

: 1 (As of Sep. 2022)
View and export this data going back to 2020. Start your Free Trial

Taysha Gene Therapies has the Profitability Rank of 1. It has had trouble to make a profit.

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way. It is based on these factors:

1. Operating Margin %
2. Piotroski F-Score
3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.
4. Consistency of the profitability
5. Predictability Rank

Taysha Gene Therapies's Operating Margin % for the quarter that ended in Sep. 2022 was %. As of today, Taysha Gene Therapies's Piotroski F-Score is 1.


Taysha Gene Therapies (NAS:TSHA) Profitability Rank Competitive Comparison

For the Biotechnology subindustry, Taysha Gene Therapies's Profitability Rank, along with its competitors' market caps and Profitability Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

   

Taysha Gene Therapies (NAS:TSHA) Profitability Rank Distribution

For the Biotechnology industry and Healthcare sector, Taysha Gene Therapies's Profitability Rank distribution charts can be found below:

* The bar in red indicates where Taysha Gene Therapies's Profitability Rank falls into.



Taysha Gene Therapies Profitability Rank Calculation

GuruFocus Profitability Rank ranks how profitable a company is and how likely the company's business will stay that way.

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Taysha Gene Therapies has the Profitability Rank of 1. It has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength. But if a company is consistently profitable, its financial strength will be stronger.

Profitability Rank is based on these factors:

1. Operating Margin %

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Taysha Gene Therapies's Operating Margin % for the quarter that ended in Sep. 2022 is calculated as:

Operating Margin %=Operating Income (Q: Sep. 2022 ) / Revenue (Q: Sep. 2022 )
=-25.074 / 0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

2. Piotroski F-Score

Warning Sign:

Piotroski F-Score of 1 is low, which usually implies poor business operation.

The zones of discrimination were as such:

Good or high score = 8 or 9
Bad or low score = 0 or 1

Taysha Gene Therapies has an F-score of 1. It is a bad or low score, which usually implies poor business operation.

3. Trend of the Operating Margin % (5-year average). The company with an uptrend profit margin has a higher rank.

4. Consistency of the profitability

5. Predictability Rank


Taysha Gene Therapies Profitability Rank Related Terms

Thank you for viewing the detailed overview of Taysha Gene Therapies's Profitability Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


Taysha Gene Therapies (NAS:TSHA) Business Description

Taysha Gene Therapies logo
Traded in Other Exchanges
N/A
Address
2280 Inwood Road, Dallas, TX, USA, 75235
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. It is advancing a deep and sustainable product portfolio of 18 gene therapy product candidates, with exclusive options to acquire four additional development programs. Its product candidates include TSHA-101, TSHA-118, TSHA-102, TSHA-103, and TSHA-104.
Executives
Sepp-lorenzino Laura director C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET, SUITE 130 CAMBRIDGE MA 02139
Reape Kathleen director C/O TAYSHA GENE THERAPIES, INC. 2280 INWOOD ROAD DALLAS TX 75235
Nolan Sean P. director C/O INTERMUNE, INC. 3280 BAYSHORE BLVD. BRISBANE CA 94005
Donenberg Phillip B. director C/O AVEXIS, INC. 2275 HALF DAY ROAD, SUITE 200 BANNOCKBURN IL 60015
Alam Kamran officer: Chief Financial Officer 350 FIFTH AVENUE, SUITE 7530 NEW YORK NY 10118
Nagendran Sukumar director C/O AVEXIS, INC., 2275 HALF DAY ROAD SUITE 160 BANNOCKBURN IL 60015
Manning Paul B director, 10 percent owner 200 GARRETT STREET SUITE S CHARLOTTESVILLE VA 22902
Session R.a. Ii director, 10 percent owner, officer: President and CEO C/O AVEXIS, INC. 2275 HALF DAY ROAD, SUITE 200 BANNOCKBURN IL 60015
Prasad Suyash officer: CMO and Head of R&D C/O AUDENTES THERAPEUTICS, INC. 101 MONTGOMERY ST., SUITE 2650 SAN FRANCISCO CA 94104

Taysha Gene Therapies (NAS:TSHA) Headlines

From GuruFocus

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
premium membership